|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozygous deletion.
|
30972500 |
2019 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244).
|
24132923 |
2013 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244).
|
24132923 |
2013 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozygous deletion.
|
30972500 |
2019 |
|
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV).
|
28928859 |
2017 |
|
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
As the presence of the p.R132H mutation in the IDH1 gene seems to be a more powerful prognostic marker than O(6)-methylguanine-DNA methyltransferase promoter status, we evaluated the presence of IDH1 mutation in Polish patients with astrocytoma, glioblastoma, oligoastrocytoma, ganglioglioma, oligodendroglioma, and ependymoma.
|
23934769 |
2014 |
|
rs118101777
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
rs118101777
|
|
|
0.020 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
rs2297440
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In the recessive model, we found two tSNPs (rs2297440 and rs6010620) associated with increased astrocytoma risk.
|
23812731 |
2013 |
|
rs2297440
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Moreover, the stratified analyses showed a decreased risk of astrocytoma associated with RTEL1 rs6089953, rs6010620 and rs2297440 (p trend = 0.022, p trend = 0.042, p trend = 0.029, respectively) as well as an increased risk of this subtype associated with RTEL1 rs4809324 (p trend = 0.033).
|
26014354 |
2015 |
|
rs1040177874
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
|
27460417 |
2016 |
|
rs121913499
|
|
|
0.010 |
GeneticVariation |
BEFREE |
IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
|
19554337 |
2009 |
|
rs12594
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox regression analysis shows that RYR2 rs12594 AA genotype and AG genotype were associated with OS of astrocytoma (AG genotype: HR = 1.62, 95% CI 1.04-2.53, p = 0.034; AA genotype: HR = 1.70, 95% CI 1.08-2.68, p = 0.021).
|
31440994 |
2019 |
|
rs137852972
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we show that expression of seipin N-glycosylation mutant N88S led to decreased triglyceride (TG) content in astrocytoma and motor neuron cell lines.
|
23250914 |
2013 |
|
rs1476157710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, an in vitro functional assay showed that S73F and S23G mutants of beta-catenin did not affect transcriptional activity in TCF-4-leuciferase reporter construct, suggesting that they may need more complex factors to participate in astrocytoma.
|
12049819 |
2002 |
|
rs16835904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis shows that RYR2 rs16835904 TC-TT genotype facilitated the risk of astrocytoma in male (OR = 1.93, 95% CI 1.15-3.24, p = 0.011).
|
31440994 |
2019 |
|
rs1695
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined GSTP1 Ile105Val polymorphism using PCR-RFLP in 80 astrocytoma and glioblastoma samples.
|
21128213 |
2010 |